Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence

@inproceedings{Rothschild2014ClinicalPO,
  title={Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence},
  author={Sacha I. Rothschild},
  booktitle={Lung Cancer},
  year={2014}
}
The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-called oncogenic driver mutations) and the development of targeted agents interfering with the tumor-promoting intracellular signaling pathways have improved the outcome for many patients… CONTINUE READING